当前位置: X-MOL 学术EMBO Mol. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RNAi to treat SARS-CoV-2-variant proofing the next generation of therapies.
EMBO Molecular Medicine ( IF 11.1 ) Pub Date : 2022-03-14 , DOI: 10.15252/emmm.202215811
Nigel A J McMillan 1 , Kevin V Morris 1 , Adi Idris 1
Affiliation  

There is an urgent need to bring new antivirals to SARS-CoV-2 to the market. Indeed, in the last 3 months, we have seen at least two new antivirals approved, molnupiravir and paxlovid. Both are older established antivirals that show some efficacy against SARS-CoV-2. The work by Chang et al (2022) in the current issue of EMBO Molecular Medicine explores the use of short interfering RNAs to directly target SARS-CoV-2 and shows that RNAi is an effective approach to reducing, or even eliminating viral replication, depending on the experimental setting. This antiviral effect results in significant prevention of infection-related pathology in animals. The key feature of this approach, besides its simplicity as naked siRNAs, is that all current variants are covered by this treatment.

中文翻译:

RNAi 治疗 SARS-CoV-2 变体证明了下一代疗法。

迫切需要将新的抗 SARS-CoV-2 抗病毒药物推向市场。事实上,在过去 3 个月中,我们看到至少有两种新的抗病毒药物获批,即莫努匹拉韦和帕索洛韦。两者都是较老的抗病毒药物,对 SARS-CoV-2 显示出一定的疗效。Chang 等人 (2022) 在当前一期 EMBO Molecular Medicine 中的工作探索了使用短干扰 RNA 直接靶向 SARS-CoV-2,并表明 RNAi 是减少甚至消除病毒复制的有效方法,具体取决于在实验设置上。这种抗病毒作用可显着预防动物的感染相关病理。这种方法的关键特征,除了它作为裸 siRNA 的简单性之外,是所有当前的变体都被这种处理所覆盖。
更新日期:2022-03-14
down
wechat
bug